KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Long-Term Deferred Tax (2016 - 2025)

Jazz Pharmaceuticals has reported Long-Term Deferred Tax over the past 14 years, most recently at $869.1 million for Q4 2025.

  • Quarterly results put Long-Term Deferred Tax at $869.1 million for Q4 2025, up 55.13% from a year ago — trailing twelve months through Dec 2025 was $869.1 million (up 55.13% YoY), and the annual figure for FY2025 was $869.1 million, up 55.13%.
  • Long-Term Deferred Tax for Q4 2025 was $869.1 million at Jazz Pharmaceuticals, up from $846.2 million in the prior quarter.
  • Over the last five years, Long-Term Deferred Tax for JAZZ hit a ceiling of $869.1 million in Q4 2025 and a floor of $258.5 million in Q1 2021.
  • Median Long-Term Deferred Tax over the past 5 years was $447.2 million (2023), compared with a mean of $468.4 million.
  • Biggest five-year swings in Long-Term Deferred Tax: grew 0.1% in 2022 and later soared 55.13% in 2025.
  • Jazz Pharmaceuticals' Long-Term Deferred Tax stood at $311.1 million in 2021, then increased by 20.94% to $376.2 million in 2022, then grew by 27.0% to $477.8 million in 2023, then grew by 17.25% to $560.2 million in 2024, then skyrocketed by 55.13% to $869.1 million in 2025.
  • The last three reported values for Long-Term Deferred Tax were $869.1 million (Q4 2025), $846.2 million (Q3 2025), and $602.9 million (Q2 2025) per Business Quant data.